Introduction: Over the last few years, the clinical success of immune checkpoint inhibitors has increasingly drawn attention to cancer therapies that target the tumor microenvironment (TME). TME consists of various cell types that are embedded in the extracellular matrix (ECM), including immune cells, endothelial cells, and cancer associated fibroblasts, all of which play critical roles …Read More >

Introduction: As a therapeutic modality, oligonucleotides have a target abundance, persistent efficacy, high specificity, greater success rate and shorter R/D development period compared to other therapeutic approaches. Recently, significant achievements have been made in the discovery of oligonucleotide drugs. Numerous oligonucleotide drugs have been marketed. However, there are still many challenges, including limited delivery efficiency …Read More >

Introduction: Cancer is a major public health concern, and this disease is a leading cause of death worldwide. There are over 200 different types of cancer, and such complexity has slowed the rate of progress being made by researchers. Encouragingly, the emergence of immunotherapies, especially tumor vaccines, brings hope to cancer patients. Personalized tumor vaccines …Read More >

Introduction: OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our large-scale cell panel screening platform for integrated pharmacogenomics and bioinformatics research. Cell viability assessment is a commonly used in …Read More >

Introduction: Nucleic acid therapies can regulate the expression level or activity of disease-related targets at the genetic level, offering advantages such as a wide target range, programmability, and rapid iteration.  However, the wide application of nucleic acid drugs still faces many challenges, including delivery efficiency and off-target effects. To address these challenges, the Oncology-Immunology team …Read More >

Introduction: WuXi AppTec scientists recently contributed to a study which led to the discovery and optimization of a novel series of GST inhibitors. The authors used affinity mediated DNA-encoded library selection against a privileged scaffold to identify a compound with potent inhibition against human glutathione S-transferase Mu 2.  SAR studies, coupled with X-ray crystallography and …Read More >

The hepatic fibrosis has been the most challenging aspect in the animal models for nonalcoholic steatohepatitis (NASH). Although it could induced by nutritional (high-fat died with high cholesterol, methionine and choline deficient diet, etc), chemical (carbon tetrachloride, thioacetamide, α-naphthylisothiocyanate etc.), and surgical (bile duct ligation) means, the clinical relevance of the resulting fibrosis remains an …Read More >

In the past, thousands of proteins were considered undruggable. The restricted number of chemical entities available and classical methods limited the exploration of this undevelopable area. Today, the combination of novel chemical modalities and advanced technical approaches has resulted in new clinical candidates from previously undruggable targets. To accelerate your drug discovery campaign, WuXi AppTec´s …Read More >